A Multicenter Phase I/II Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel With or Without NPC-1C in Patients With Metastatic or Locally Advanced Pancreatic Cancer Previously Treated With FOLFIRINOX

Trial Profile

A Multicenter Phase I/II Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel With or Without NPC-1C in Patients With Metastatic or Locally Advanced Pancreatic Cancer Previously Treated With FOLFIRINOX

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs Ensituximab (Primary) ; Gemcitabine; Paclitaxel
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Precision Biologics
  • Most Recent Events

    • 15 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 20 Aug 2015 According to a Precision Biologics media release, Beth Israel Deaconess Medical Center (BIDMC) has joined Precision Biologics as Collaborators for this study.
    • 18 May 2015 Yale Cancer Center at the Yale School of Medicine and the University of North Carolina at Chapel Hill (UNC) have joined Precision Biologics as collaborators for this trial, according to a company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top